A case of bullous pemphigoid successfully treated by plasmapheresis: Assessment of the change in titers of circulating antibodies by immunoblotting and enzyme-linked immunosorbent assay

Journal of Dermatology

Volumn 30, Issue 4, 2003, Pages 326-331

  Lee, Jee Bum ^a,b   Fumimori, Takeaki ^a   Kurose, Koichiro ^a   Mori, Osamu ^a   Hashimoto, Takashi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Bullous pemphigoid; Enzyme linked immunosorbent assay; Immunoblotting; Plasmapheresis

Indexed keywords

AUTOANTIBODY; RECOMBINANT PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; MALE; PEMPHIGOID; PLASMAPHERESIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0038333284     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2003.tb00395.x     Document Type: Article

References (10)

1. Roujeau JC, Kalis B, Lauret P, et al: Plasma exchange in corticostroid-resistant pemphigus, Br J Dermatol, 106: 103-104, 1982.
2. Goldberg NS, Robinson JK, Roenigk Jr HH, Marder R, Rothe M: Plasmapheresis therapy for bullous pemphigoid, Arch Dermatol, 121: 1484-1485, 1985.
3. Zillikens D, Mascaro JM, Rose PA, et al: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid, J Invest Dermatol 109: 679-683, 1997.
4. Tanaka M, Hashimoto T, Amagai M, et al: Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins, J Invest Dermatol. 97: 725-728, 1991.
5. Nakatani C, Muramatsu T, Shirai T: Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180kDa BP antigen (BP180): Immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins, Br J Dermatol, 139: 365-370, 1998.
6. Matsumura K, Hashimoto T, Ohata Y, Nishikawa T: Majority of bullous pemphigoid and herpes gestationis sera react with NC16a domain of the 180 kD bullous pemphigoid antigen, Arch Dermatol Res, 288: 507-509, 1996
7. Sugi T, Hashimoto T, Hibi T, Nishikawa T: Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation: Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them, J Clin Invest, 84: 1050-5, 1989.
8. Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ: Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid, J Immunol, 155: 5449-5454, 1995.
9. Zillikens D, Rose PA, Balding SD, et al: Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies, J Invest Dermatol, 109: 573-579, 1997.
10. Roujeau JC, Guillaume JC, Morel P, et al: Plasmapheresis exchange in bullous pemphigoid, Lancet, 2: 486-489, 1984.